The SHIELD COVID-19 Study is Enrolling!
We invite healthcare workers who are interacting with patients with suspected or known COVID-19 to participate.
Contact email@example.com for more information, or visit shield.medicine.wisc.edu.
Our team, led by Dr. Nasia Safdar, is focused on clinical research and quality improvement measures aimed at reducing healthcare-associated infections (HAIs) and the rise of multi-drug resistant organisms (MDROs). We also are actively investigating the role of the microbiome in health and disease. Our objective is to find novel approaches to prevent and treat healthcare-associated infections, particularly in the acute care setting.
PATIENT-ORIENTED RESEARCH AND CLINICAL TRIALS
Our clinical research program focuses on reducing the occurrence of healthcare-associated infections (HAIs) and improving interventions for these infections with an emphasis on reducing the burden of multi-drug resistant infections (MDROs).
- C. difficile in the Healthcare Setting: Clostridium difficile (C. difficile) is a pathogen of major public health importance and the most common cause of healthcare-associated diarrhea, with high rates of recurrent disease. Over one third of patients who develop CDI will develop one or more recurrences and the risk of subsequent recurrence increases with each episode.
Through our clinical trials we aim to prevent and reduce the recurrence of C. difficile in our patients and subsequently reduce the burden it has both financially and physically for those that have been affected.
Current Clinical Trials
This trial aims to evaluate the efficacy of daily prophylactic vancomycin for preventing recurrent Clostridium difficile infection (CDI). Those who have been diagnosed with a C. diff infection in the past 6 months and will receive antibiotics for a reason other than C. diff may be eligible to join.
This trial aims to evaluate the efficacy of a single FMT enema treatment for preventing recurrent Clostridium difficile infection (CDI). Those who are currently being treated with antibiotics for a recurrent C. diff infection may be eligible to join.
This trial aims to evaluate the efficacy of a single FMT enema treatment compared to oral vancomyocin treatment for preventing recurrent Clostridium difficile infection (CDI) in Solid Organ Transplant recipients. Those who have had a Solid Organ Transplant (SOT) and are currently receiving treatment for a recurrent C. diff infection may be eligible to join.